The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Open accessAbstract
BACKGROUND: mutation make up a small subgroup of those with metastatic pancreatic cancer. The poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib has had antitumor activity in this population. METHODS: mutation and metastatic pancreatic cancer and disease that had not progressed during first-line platinum-based chemotherapy. Patients were randomly assigned, in a 3:2 ratio, to receive maintenance olaparib tablets (300 mg twice daily) or placebo. The primary end point was progression-free survival, which was assessed by blinded independent central review. RESULTS: Of the 3315 patients who underwent screening, 154 underwent randomization and were assigned to a trial intervention (92 to receive olaparib and 62 to receive placebo). The median progression-free survival was significantly longer in the olaparib group than in the placebo group (7.4 months vs. 3.8 months; hazard ratio for disease progression or death, 0.53; 95% confidence interval [CI], 0.35 to 0.82; P = 0.004). An interim analysis of overall survival, at a data maturity of 46%, showed no difference between the olaparib and placebo groups (median, 18.9 months vs. 18.1 months; hazard ratio for death, 0.91; 95% CI, 0.56 to 1.46; P = 0.68). There was no significant between-group difference in health-related quality of life, as indicated by the overall change from baseline in the global quality-of-life score (on a 100-point scale, with higher scores indicating better quality of life) based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (between-group difference, -2.47 points; 95% CI, -7.27 to 2.33). The incidence of grade 3 or higher adverse events was 40% in the olaparib group and 23% in the placebo group (between-group difference, 16 percentage points; 95% CI, -0.02 to 31); 5% and 2% of the patients, respectively, discontinued the trial intervention because of an adverse event. CONCLUSIONS: mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo. (Funded by AstraZeneca and others; POLO ClinicalTrials.gov number, NCT02184195.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“HRD targeted therapy with PARPi is mostly restricted to breast and ovarian cancer5, though its use for treating pancreatic cancer was recently approved by the FDA (US Food and Drug Administration)29.”
From Pan-cancer landscape of homologous recombination deficiency. (2020) · cites this paper as [29]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredIn the citing paper
“Finally, in late-stage PDAC with germline mutation in BRCA1 or BRCA2 (~7.5% of the patients), the PARP inhibitor olaparib could extend progression free survival but not overall survival (8).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [8]
In the citing paper
“a pivotal clinical trial in patients with PDAC and germline BRCA1/2 mutations established the benefit of administering an orally bioavailable PARP inhibitor on improved progression free survival (PFS). This led to the approval of targeted therapy in this setting87.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citationOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642
Self-citationEpidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Rawla, P., Sunkara, T., & Gaduputi, V. (2019) · World Journal of Oncology · doi:10.14740/wjon1166 · Cited by 2,269
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,002
The Role of Germline Mutations in Thoracic Malignancies: Between Myth and Reality
Farinea, G., Crespi, V., Listì, A., Righi, L., Bironzo, P., Merlini, A., Malapelle, U., Novello, S., Scagliotti, G. V., & Passiglia, F. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.05.028 · Cited by 21
Park, S., Kim, Y. J., Min, Y. J., Mortimer, P. G. S., Kim, H., Smith, S. A., Dean, E. J., Jung, H. A., Sun, J., Park, W., et al. (2023) · Cancer · doi:10.1002/cncr.35059 · Cited by 23
Ahn, D. H., & Bekaii‐Saab, T. (2020) · Chinese Clinical Oncology · doi:10.21037/cco.2020.02.02 · Cited by 23
Seghers, A.-K., Cuyle, P.-J. A., & Cutsem, E. V. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00727-9 · Cited by 22
Gower, A., Golestany, B., Gong, J., Singhi, A. D., & Hendifar, A. E. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00365 · Cited by 23
Ammendola, M., Currò, G., Laface, C., Zuccalà, V., Memeo, R., Luposella, F., Laforgia, M., Zizzo, N., Zito, A., Loisi, D., et al. (2021) · Cells · doi:10.3390/cells10020444 · Cited by 23
Comprehensive analysis of DNA damage repair deficiency in 10,284 pan–cancer study
Xiao, Y., Lu, D., Lei, M., Xie, W., Chen, Y., Zheng, Y., Wang, C., Zhao, J., Zhu, Z., Zhao, X., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-5449 · Cited by 22
Saha, A., Zhao, S., Chen, Z., Georgiou, G., Stone, E. M., Kidane, D., & DiGiovanni, J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.016 · Cited by 24
The role of phosphoprotein phosphatases catalytic subunit genes in pancreatic cancer
Hang, J., Lau, S. Y. F., Yin, R., Zhu, L., Zhou, S., Yuan, X., & Wu, L. (2020) · Bioscience Reports · doi:10.1042/bsr20203282 · Cited by 21
Drivers of Gene Expression Dysregulation in Pancreatic Cancer
Venkat, S., Alahmari, A. A., & Feigin, M. E. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.01.008 · Cited by 23
Green, M. F., Bell, J. L., Hubbard, C. B., McCall, S. J., McKinney, M. S., Riedel, J., Menendez, C. S., Abbruzzese, J. L., Strickler, J. H., & Datto, M. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00030 · Cited by 24
Assénat, E., de la Fouchardière, C., Portales, F., Ychou, M., Debourdeau, A., Desseigne, F., Iltache, S., Fiess, C., Mollévi, C., & Mazard, T. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100318 · Cited by 22
A review on mechanisms of resistance to PARP inhibitors
Desai, C. J., Pathak, A. B., Limaye, S. A., Maniar, V., & Joshi, A. (2022) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_53_21 · Cited by 23
Ashida, R., & Kitano, M. (2022) · Digestive Endoscopy · doi:10.1111/den.14344 · Cited by 23
Xu, J.-Y., Guan, W., Lu, S., Wei, X., Shi, W.-J., Ren, C., Li, Y., Li, S., Qiu, M., & Wang, F. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549221090186 · Cited by 22
Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care
Casolino, R., Corbo, V., Beer, P. A., Hwang, C., Paiella, S., Silvestri, V., Ottini, L., & Biankin, A. V. (2022) · Cancers · doi:10.3390/cancers14133239 · Cited by 24
Ngoi, N. Y. L., Westin, S. N., & Yap, T. A. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000867 · Cited by 23
NUPR1 protects against hyperPARylation-dependent cell death
Santofimia‐Castaño, P., Huang, C., Liu, X., Xia, Y., Audebert, S., Camoin, L., Peng, L., Lomberk, G. A., Urrutia, R. A., Soubeyran, P., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03705-1 · Cited by 22
Bastos, I. F., Rebelo, S., & Silva, V. L. M. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116045 · Cited by 23
Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options
Bitzer, M., Ostermann, L., Horger, M., Biskup, S., Schulze, M., Ruhm, K., Hilke, F. J., Öner, Ö., Nikolaou, K., Schroeder, C., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00359 · Cited by 22
Current controversies and advances in the management of pancreatic adenocarcinoma
Zeeshan, M. S., & Ramzan, Z. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i6.472 · Cited by 22
Bao, S., Yue, Y., Hua, Y., Zeng, T., Yang, Y., Yang, F., Yan, X., Sun, C., Yang, M., Fu, Z., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-1883 · Cited by 22
Hong, W.-F., Zhang, F., Wang, N., Bi, J.-M., Zhang, D.-W., Wei, L., Song, Z., Mills, G. B., Chen, M., Li, X., et al. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101115 · Cited by 22
Qin, C., Li, T., Chen, L., Zhao, B., Li, Z., Zhao, Y., & Wang, W. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03456-5 · Cited by 25
Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase Inhibitors
Ray, A., & Opyrchal, M. (2025) · Current Breast Cancer Reports · doi:10.1007/s12609-025-00582-5 · Cited by 23
Park, W., O'Connor, C. A., Chou, J. F., Hilmi, M., Tarcan, Z. C., Schwartz, C., Larsen, M., Homsi, R., Sivaprakasam, K., Umeda, S., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04299-5 · Cited by 24
Self-citationPoly( ADP ‐ribose) polymerase inhibition in pancreatic cancer
Singh, H. M., Bailey, P. J., Hübschmann, D., Berger, A. K., Neoptolemos, J. P., Jäger, D., Siveke, J. T., & Springfeld, C. (2020) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22932 · Cited by 22
CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors
Xu, Z., Vandenberg, C. J., Lieschke, E., Rago, L. D., Scott, C. L., & Majewski, I. J. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0791 · Cited by 22
Poon, D., Tan, M. H., & Khor, D. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-244271 · Cited by 21
Stoof, J., Harrold, E. C., Mariottino, S., Lowery, M. A., & Walsh, N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.749490 · Cited by 21
Suzuki, T., Masugi, Y., Inoue, Y., Hamada, T., Tanaka, M. H., Takamatsu, M., Arita, J., Kato, T., Kawaguchi, Y., Kunita, A., et al. (2022) · Cancer Science · doi:10.1111/cas.15398 · Cited by 21
Puccini, A., Ponzano, M., Dalmasso, B., Vanni, I., Gandini, A., Puglisi, S., Borea, R., Cremante, M., Bruno, W., Andreotti, V., et al. (2022) · Cancers · doi:10.3390/cancers14184447 · Cited by 21
Nero, C., Duranti, S., Giacomini, F., Minucci, A., Giacò, L., Piermattei, A., Genuardi, M., Pasciuto, T., Urbani, A., Daniele, G., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101746 · Cited by 20
Self-citationManagement of Patients With Pancreatic Cancer Using the “Right Track” Model
Rosenzweig, A., Berlin, J. D., Chari, S. T., Kindler, H. L., Matrisian, L. M., Mayoral, A., Mills, J. B., Nissen, N. N., Picozzi, V. J., Zelada-Arenas, F., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad080 · Cited by 20
Self-citationTargeting DNA damage repair precision medicine strategies in cancer
Brownlie, J., Kulkarni, S., Algethami, M., Jeyapalan, J. N., Mongan, N. P., Rakha, E. A., & Madhusudan, S. (2023) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2023.102381 · Cited by 22
Early-Onset GI Cancers: Rising Trends, Genetic Risks, Novel Strategies, and Special Considerations
Harrold, E., Latham, A. J., Pemmaraju, N., & Lieu, C. H. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_398068 · Cited by 22
Martino, C., Pandya, D. S., Lee, R. D., Levy, G. H., Lo, T., Lobo, S., & Frank, R. C. (2019) · Pancreas · doi:10.1097/mpa.0000000000001461 · Cited by 21
Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC
Digiacomo, G., Volta, F., Garajová, I., Balsano, R., & Cavazzoni, A. (2021) · Life · doi:10.3390/life11080843 · Cited by 21
Structural basis for a Polθ helicase small-molecule inhibitor revealed by cryo-EM
Ito, F., Li, Z., Станиславович, М. Л., Chandramouly, G., Tyagi, M., Betsch, R. G., Krais, J. J., Taberi, B., Vekariya, U. M., Calbert, M. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51351-4 · Cited by 20
Organoid‐based precision medicine in pancreatic cancer
Beutel, A. K., Ekizce, M., Ettrich, T. J., Seufferlein, T. T. W., Lindenmayer, J., Gout, J., & Kleger, A. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12701 · Cited by 21
Novel Therapies for Pancreatic Cancer
Chung, V., Mizrahi, J. D., & Pant, S. (2024) · JCO Oncology Practice · doi:10.1200/op.24.00279 · Cited by 20
Kerle, I. A., Gross, T. J., Kögler, A., Arnold, J. S., Werner, M., Eckardt, J., Möhrmann, E. E., Arlt, M., Hutter, B., Hüllein, J., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-024-00788-3 · Cited by 24
[18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma
Harder, F. N., Jungmann, F., Kaissis, G. A., Lohöfer, F. K., Ziegelmayer, S., Havel, D., Quante, M., Reichert, M., Schmid, R. M., Demir, İ. E., et al. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00808-4 · Cited by 20
Current understanding of ferroptosis in the progression and treatment of pancreatic cancer
Dong, S., Li, X., Jiang, W., Chen, Z., & Zhou, W. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02166-6 · Cited by 21
Botrus, G., Usón, P. L. S., Raman, P., Kaufman, A. E., Kosiorek, H., Yin, J., Fu, Y., Majeed, U., Sonbol, M. B., Ahn, D. H., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.794009 · Cited by 20
Intra-Arterial Infusion Chemotherapy in Advanced Pancreatic Cancer: A Comprehensive Review
Laface, C., Laforgia, M., Molinari, P., Foti, C., Ambrogio, F., Gadaleta, C. D., & Ranieri, G. (2022) · Cancers · doi:10.3390/cancers14020450 · Cited by 20
Insights into the Possible Molecular Mechanisms of Resistance to PARP Inhibitors
Piombino, C., & Cortesi, L. (2022) · Cancers · doi:10.3390/cancers14112804 · Cited by 21
DNA repair deficiency as circulating biomarker in prostate cancer
Catalano, M., Generali, D., Gatti, M., Riboli, B., Paganini, L., Nesi, G., & Roviello, G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1115241 · Cited by 20
New Treatment Options in Metastatic Pancreatic Cancer
Fudalej, M. M., Kwaśniewska, D., Nurzyński, P., Badowska-Kozakiewicz, A. M., Mękal, D., Czerw, A. I., Sygit, K., & Deptała, A. (2023) · Cancers · doi:10.3390/cancers15082327 · Cited by 20
Advancements in Systemic Therapy for Pancreatic Cancer
Brown, T. J., Reiss, K. A., & O’Hara, M. H. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_397082 · Cited by 21
Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies
Huynh, J. C., Schwab, E., Ji, J., Kim, E. J.-H., Joseph, A., Hendifar, A. E., Cho, M. T., & Gong, J. (2020) · Cancers · doi:10.3390/cancers12051168 · Cited by 23
Sigorski, D., Iżycka‐Świeszewska, E., & Bodnar, L. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00756-4 · Cited by 21
Principe, D. R., Narbutis, M., Koch, R. M., & Rana, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-76975-6 · Cited by 20
Archibugi, L., Ruta, V., Panzeri, V., Redegalli, M., Testoni, S. G. G., Petrone, M. C., Rossi, G., Falconi, M., Reni, M., Doglioni, C., et al. (2020) · Cells · doi:10.3390/cells9122561 · Cited by 20
Self-citationClinical Characteristics of Patients With Pancreatic Cancer and Pathogenic ATM Alterations
Hannan, Z. M., Yu, S., Domchek, S. M., Mamtani, R., & Reiss, K. A. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa121 · Cited by 20
Application of single-cell sequencing technologies in pancreatic cancer
Mannarapu, M., Dariya, B., & Bandapalli, O. R. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04095-4 · Cited by 20
Cytotoxic and targeted therapy for BRCA1/2-driven cancers
Имянитов, Е. Н. (2021) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-021-00193-y · Cited by 20
Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards
Fujiwara, Y., Kato, S., & Kurzrock, R. (2026) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2026.05.019 · Cited by 22
The Landscape of PARP Inhibitors in Solid Cancers
Muzzana, M., Broggini, M., & Damia, G. L. M. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s499226 · Cited by 19
Bever, K. M., Borazanci, E. H., Thompson, E. A., Durham, J. N., Pinero, K., Jameson, G., Vrana, A., Liu, M., Wilt, C., Wu, A. A., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27586 · Cited by 19
Rinaldi, Y., Pointet, A., Akouz, F. K., Malicot, K. L., Wahiba, B., Louafi, S., Gratet, A., Miglianico, L., Laharie, H., Leporrier, K. B., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.05.018 · Cited by 19
Taı̈eb, J., & Abdallah, R. (2019) · ESMO Open · doi:10.1136/esmoopen-2020-000818 · Cited by 19
Gao, Y., Chen, M., Chu, Y., Yang, L., Yu, D., Liu, Y., & Hung, M. (2021) · PubMed Central · Cited by 19
Novel systemic treatment approaches for metastatic pancreatic cancer
Dorman, K., Heinemann, V., Kobold, S., von Bergwelt‐Baildon, M., & Boeck, S. H. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2037552 · Cited by 19
Huart, C., Fransolet, M., Demazy, C., Calvé, B. L., Lucas, S., Michiels, C., & Wéra, A.-C. (2022) · Cancers · doi:10.3390/cancers14061460 · Cited by 19
Xu, Z., Wang, W., Lou, W., & Liu, L. (2022) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000093 · Cited by 18
Dardare, J., Witz, A., Betz, M., François, A., Meras, M., Lamy, L., Lambert, A., Grandemange, S., Husson, M., Rouyer, M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1052163 · Cited by 18
Iwaya, H., Tanimoto, A., Toyodome, K., Kojima, I., Hinokuchi, M., Tanoue, S., Hashimoto, S., Kawahira, M., Arima, S., Kanmura, S., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13061078 · Cited by 19
Shirakawa, T., Makiyama, A., Shimokawa, M., Otsuka, T., Shinohara, Y., Koga, F., Ueda, Y., Nakazawa, J., Otsu, S., Komori, A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-34962-7 · Cited by 19
Thavaneswaran, S., Kansara, M., Lin, F., Espinoza, D., Grady, J. P., Lee, C. K., Ballinger, M. L., Sebastian, L. T., Corpuz, T. M., Qiu, M. R., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02311-0 · Cited by 19
Phan, Z., Ford, C. E., & Caldon, C. E. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106927 · Cited by 19
Orlandi, E., Citterio, C., Anselmi, E., Cavanna, L., & Vecchia, S. (2024) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10303 · Cited by 19
Current Approaches to Germline Cancer Genetic Testing
Stoffel, E. M., & Carethers, J. M. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-052318-101009 · Cited by 22
Imaging and Management of Pancreatic Cancer
Kobi, M., Veillette, G. R., Narurkar, R., Sadowsky, D., Paroder, V., Shilagani, C., Gilet, A. G., & Flusberg, M. (2019) · Seminars in Ultrasound CT and MRI · doi:10.1053/j.sult.2019.12.003 · Cited by 18
Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives
Reverdy, T., Sajous, C., Péron, J., Gléhen, O., Bakrin, N., Gertych, W., Lopez, J., You, B., & Freyer, G. (2020) · Cancers · doi:10.3390/cancers12092414 · Cited by 19
Sun, W., Li, J., Zhang, Z., & Su, X. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13300 · Cited by 20
Su, D., Wu, B. Y., & Shi, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.610601 · Cited by 19
Imaoka, H., Sasaki, M., Hashimoto, Y., Watanabe, K., Miyazawa, S., Shibuki, T., Mitsunaga, S., & Ikeda, M. (2021) · Diagnostics · doi:10.3390/diagnostics11071195 · Cited by 19
Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives
Lellouche, L., Palmieri, L., Dermine, S., Brézault, C., Chaussade, S., & Coriat, R. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211018539 · Cited by 19
Genta, S., Martorana, F., Stathis, A., & Colombo, I. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103539 · Cited by 20
Advanced Bile Duct Cancers: A Focused Review on Current and Emerging Systemic Treatments
Cowzer, D., & Harding, J. J. (2022) · Cancers · doi:10.3390/cancers14071800 · Cited by 19
Gu, L., Du, N., Jin, Q., Li, S., Xie, L., Mo, J., Shen, Z., Mao, D., Ji, J., Khadaroo, P. A., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102888 · Cited by 19
Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Wu, B. Y., & Shi, L. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7587 · Cited by 20
Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer
Iovanna, J. (2021) · Translational Oncology · doi:10.1016/j.tranon.2020.100965 · Cited by 18
Xiao, M., Tang, R., Pan, H., Yang, J. H., Tong, X., Xu, H., Guo, Y., Lei, Y., Wu, D., Lei, Y., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-332782 · Cited by 19
Pancreatic organoids as cancer avatars for true personalized medicine
Gout, J., Ekizce, M., Roger, É., & Kleger, A. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115642 · Cited by 20
Understanding the heterogeneity of pancreatic ductal adenocarcinoma
Iovanna, J., Fraunhoffer, N. A., Urrutia, R. A., & Dusetti, N. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102479 · Cited by 20
Patient-derived xenograft models of BRCA-associated pancreatic cancers
Golan, T., Atias, D., Stossel, C., & Raitses‐Gurevich, M. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.010 · Cited by 18
Self-citationTumour microenvironment and heterotypic interactions in pancreatic cancer
Velasco, R. M., García, A. G., Sánchez, P. J., Sellart, I. M., & Lobo, V. J. S.-A. (2022) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-022-00875-8 · Cited by 18
Bieńkowski, M., Tomasik, B., Braun, M., & Jassem, J. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102359 · Cited by 19
Recent advances in understanding pancreatic cancer
Stott, M. C., Oldfield, L. S., Hale, J. J., Costello, E., & Halloran, C. M. (2022) · Faculty Reviews · doi:10.12703/r/11-9 · Cited by 19
Qian, Y., Gong, Y., Zou, X., Liu, Y., Chen, Y., Wang, R., Dai, Z., Tasiheng, Y., Lin, X., Wang, X., et al. (2022) · Oncogenesis · doi:10.1038/s41389-022-00411-9 · Cited by 18
The molecular landscape of pancreatic ductal adenocarcinoma
Sivapalan, L., Kocher, H. M., Ross‐Adams, H., & Chelala, C. (2022) · Pancreatology · doi:10.1016/j.pan.2022.07.010 · Cited by 21
Busato, D., Mossenta, M., Bo, M. D., Macor, P., & Toffoli, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810279 · Cited by 18
Genetics, Genomics and Emerging Molecular Therapies of Pancreatic Cancer
Liu, J., Mroczek, M., Mach, A., Stępień, M., Aplas, A., Pronobis‐Szczylik, B., Bukowski, S., Mielczarek, M., Gajewska, E., Topolski, P., et al. (2023) · Cancers · doi:10.3390/cancers15030779 · Cited by 18
The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes
Kayıkçıoğlu, E., & Yüceer, R. O. (2023) · Medicine · doi:10.1097/md.0000000000032882 · Cited by 20
Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency
Li, W., Gao, L., Yi, X., Shi, S., Huang, J., Shi, L. M., Zhou, X., Wu, L., & Ying, J. (2023) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2023.02.004 · Cited by 19
Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival
Urbanova, M., Cihova, M., Buociková, V., Slopovský, J., Dubovan, P., Pinďák, D., Tomáš, M., García‐Bermejo, L., Rodríguez-Garrote, M., Earl, J., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115179 · Cited by 19
Obesity associated pancreatic ductal adenocarcinoma: Therapeutic challenges
Srilatha, M., Malla, R. R., Adem, M. P., Foote, J. B., & Nagaraju, G. P. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.11.002 · Cited by 19
Alruwaili, M., Zonneville, J., Naranjo, M. N., Serio, H., Melendy, T., Straubinger, R. M., Gillard, B. M., Foster, B. A., Rajan, P., Attwood, K. M., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101434 · Cited by 18
Metadata
- Authors
- Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., Reinacher-Schick, A., Tortora, G., Algül, H., O’Reilly, E. M., McGuinness, D., Cui, K. Y., Schlienger, K., Locker, G. Y., & Kindler, H. L.
- Affiliations
- Tel Aviv University (IL)
- From the Oncology Institute, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (T.G.); Hôpital Beaujon (Assistance Publique–Hôpitaux de Paris), Clichy, and University Paris VII, Paris (P.H.); IRCCS Ospedale San Raffaele Scientific Institute, Milan (M.R.), Azienda Ospedaliera Universitaria Integrata Verona, Verona (G.T.), and Fondazione Policlinico Universitario Gemelli IRCCS, Rome (G.T.) — all in Italy; University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium (E.V.C.); Vall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-07-25
- Volume
- 381
- Issue
- 4
- Pages
- 317-327
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6810605
- OpenAlex
- W2947826965
- Cited by
- 2,302
- References
- 24
- Citations by year
- 2026: 195 · 2025: 268 · 2024: 292 · 2023: 312 · 2022: 412 · 2021: 452 · 2020: 299 · 2019: 66
- FWCI
- 129.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, cc-by-nc-nd)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- AstraZeneca (NA)
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc (NA)
- NIH/NCI Cancer Center Support Grant (P30-17 CA008748)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- olaparib, PARP inhibitors, germline BRCA mutation, metastatic pancreatic cancer, maintenance therapy, progression-free survival, overall survival, quality of life, adverse events, platinum-based chemotherapy, PARP inhibitor resistance, DNA repair deficiency, targeted therapy, interim analysis, predictive biomarkers, treatment discontinuation, health-related quality of life
- MeSH terms
- Progression-Free Survival, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Double-Blind Method, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Pancreatic Neoplasms, Phthalazines, Piperazines, Germ-Line Mutation, Genes, BRCA1, Genes, BRCA2, Kaplan-Meier Estimate, Maintenance Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
